Mary Abdulky, MD
Rheumatology · Syracuse, NYNPI 1821060153
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,044 of the $1,364 with a category attached, or 76.5%. It is spread thinly across 15 manufacturers, the largest accounting for just 18.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $736 and has fallen 88.7% since, to $83 in 2025. That places this record below the midpoint for rheumatology clinicians in NY, where the typical reported total is $1,764.
Across 34 payments — averaging $40.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$256
- Johnson & Johnson$210
- Aurinia Pharma U.S., Inc.$176
- Genentech USA, Inc.$134
- AbbVie$127
- Lilly USA, LLC$104
- plus $357 from 9 others
Across 1 payment — averaging $3478.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$3K
What the payments were for
- Food & beverage$1,04476%
- Education$32124%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 8 | $256 |
| Johnson & Johnson | 3 | $210 |
| Aurinia Pharma U.S., Inc. | 4 | $176 |
| Genentech USA, Inc. | 3 | $134 |
| AbbVie | 3 | $127 |
| Lilly USA, LLC | 1 | $104 |
| Boehringer Ingelheim | 2 | $90 |
| UCB, Inc. | 1 | $86 |
| AstraZeneca | 3 | $53 |
| Fresenius Kabi USA, LLC | 1 | $30 |
| Radius Health, Inc. | 1 | $26 |
| Werfen USA LLC | 1 | $19 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $18 |
| Pfizer | 1 | $18 |
| Scilex Pharmaceuticals Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,364 in reported general payments places this provider in the 45th percentile of 541 rheumatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxychloroquine Sulfate | 100 | $3,130 |
| MethotrexateMethotrexate Sodium | 135 | $2,140 |
| Sulfasalazine DrSulfasalazine | 31 | $1,264 |
| Prednisone | 140 | $830 |
| Celecoxib | 18 | $322 |
| Allopurinol | 24 | $130 |
| Folic Acid | 30 | $120 |
| Methylprednisolone | 17 | $108 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Syracuse
- Laurie GlimcherNew York$3.9M
- Grace WrightNew York$3M
- Kostas BotsoglouCheektowaga$2.6M
- Sergio SchwartzmanNew York$2.5M
- Allan GibofskyNew York$1.9M
- Petros EfthimiouNew York$791K
- Richard FurieNew Hyde Park$746K
- Barry GruberBabylon$742K
- Olga PetrynaNew York$509K
- Sanjay GodhwaniWading River$472K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.